Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 08, 2026 08:30 ET | Source: Tris Pharma, Inc.

Tris Pharma Announces Acceptance of New Publication Highlighting Promise of Dual NOP-MOP (dual-NMR) Agonists for the Treatment of Moderate-to-Severe Pain

– Preferential MOP agonists such as oxycodone are often required for effective management of moderate to severe pain but come with significant risks of addiction and overdose – – With Dual NMR...